DOCSLIB.ORG

Poster Session a Wednesday, February 17, 2016 5:30 P.M.-7:30 P.M

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Poster Session a Wednesday, February 17, 2016 5:30 P.M.-7:30 P.M Poster Session A Wednesday, February 17, 2016 5:30 p.m.-7:30 p.m. Regency Ballroom Cancer genomes A001 Estrogen-mediated amplification of enhancers leads to aberrant oncogene expression in advanced ER alpha-positive breast cancer. Tim H.-M. Huang. A002 Amplification and overexpression of the EMSY gene in NSCLC. Ayse N Buyru, Onur Baykara , Bulut Pelin, Mehmet Dalay. A003 Genetic and histological stability of 1p/19q co-deleted gliomas at recurrence. Koki Aihara, Keisuke Ueki, Akitake Mukasa, Hiroyuki Aburatani, Phyo Kim. A004 Acid suppression required to generate gastric carcinoid tumors in mice with deleted Men1 and Somatostatin loci. Sinju Sundaresan, Anthony Kang, Juanita L Merchant. A005 Metastatic pathway-specific transcriptome analysis identifies MFSD4 as a putative tumor suppressor and biomarker for hepatic metastasis in patients with gastric cancer. Mitsuro Kanda, Dai Shimizu, Haruyoshi Tanaka, Satoshi Sueoka, Naoki Iwata, Masamichi Hayashi, Daisuke Kobayashi, Chie Tanaka, Suguru Yamada, Tsutomu Fujii, Goro Nakayama, Hiroyuki Sugimoto, Masahiko Koike, Michitaka Fujiwara, Yasuhiro Kodera. A006 Germline PARP4 mutations in patients with primary thyroid and breast cancers. Yuji Ikeda, Kazuma Kiyotani, Poh Yin Yew, Kato Taigo , Kenji Tamura, Kai Lee Yap, Sarah M Nielsen, Jessica L Mester, Raymon H Grogan, Charis Eng, Yusuke Nakamura. A007 Cancer evolution simulation identifies possible principles underlying intratumor heterogeneity. Atsushi Niida, Satoru Miyano. A008 Low-frequency mutational heterogeneity of breast cancer subtypes, including TNBC, revealed by sensitive and quantitative allele-specific PCR analyses. Meagan B Myers, Malathi Banda, Nysia I George, Karen L McKim, Barbara L Parsons. A009 Integrated genomic characterization of non-small cell lung cancer cell lines. Sakae Saito, Ikuko N Motoike, Kengo Kinoshita, Jun Yasuda, Hirofumi Ishii, Masayuki Yamamoto. A010 Using mutational signatures to dissect the role of aristolochic acid in renal cell carcinoma and other cancers. Margaret L Hoang, Chung-Hsin Chen, Pau-Chung Chen, Viktoriya S Sidorenko, Kathleen G Dickman, Byeong Hwa Yun, Masaaki Moriya, Robert J Turesky, Yeong-Shiau Pu, Bert Vogelstein, Nickolas Papadopoulos, Arthur P Grollman, Kenneth W Kinzler, Thomas A Rosenquist. A011 DNA copy number gains in malignant pleural mesothelioma. Masashi Furukawa, Shinichi Toyooka, Tatsuro Hayashi, Hiromasa Yamamoto, Nobukazu Fujimoto, Junichi Soh, Shinsuke Hashida, Kazuhiko Shien, Hiroaki Asano, Keisuke Aoe, Kazunori Okabe, Harvey I Pass, Kazunori Tsukuda, Takumi Kishimoto, Shinichiro Miyoshi. A012 Targeted Next-Generation Sequencing Panel for Detection of Mutations in Breast Cancer. Hsuan-Yu Chen, Yi-Chiung Hsu, Sung-Liang Yu, Huei-Wen Chen, Jeremy J.W. chen, Sheng- Fang Su, Ker-Chau Li. A013 Two-step forward genetic screens in mice identified multiple hepatocellular carcinoma driver genes and a new therapeutic target. Takahiro Kodama, Justin Newberg, Robert Rangel, Michiko Kodama, Kosuke Yoshihara, Nancy Jenkins, Neal Copeland. A014 Genome-wide approach to pediatric pancreatoblastoma. Masafumi Seki, Isobe Tomoya, Kenichi Yoshida, Yuichi Shiraishi, Kenichi Chiba, Hiroko Tanaka, Yusuke Sato, Keisuke Kataoka, Yoichi Fujii, Hiromichi Suzuki, Teppei Shimamura, Motohiro Kato, Akihiro Iguchi, Asahito Hama, Tomoaki Taguchi, Yukichi Tanaka, Junya Fujimura, Akiko Inoue, Tsuyoshi Ito, Takao Deguchi, Satoru Miyano, Yasuhide Hayashi, Akira Oka, Seishi Ogawa, Junko Takita. A015 Clonal origin of therapy-related myeloid neoplasms. Koichi Takahashi, Feng Wang, Hagop Kantarjian, Doss Denaha, Erika Thompson, Keyur Patel, Sattva Neelapu, Curtis Gumbs, Yan Wang, Zachary Bohannan, Coutney DiNardo, Simona Colla, Jianhua Zhang, Xifeng Wu, Guillermo Garcia- Manero, Andrew Futreal. A016 Molecular epidemiological analysis of oral cancer in the Indian population reveals region- specific differences in the spectrum of driver mutations and oncogenic pathways. Ravi Gupta, Vedam Laxmi Ramprasad, Kartik Kumaramangalam, Arati Khanna Gupta, Sam Santhosh, Amitabha Chaudhuri. A018 DNA probes in the genetic diagnosis and its prognostic factors of Kazakh esophageal cancer patients. Maidiniyeti Niyazi. A019 Detection of multiple low-frequency mutations by molecular-barcode sequencing. Kei Namba, Shuta Tomida, Ken Suzawa, Hiromasa Yamamoto, Yuho Maki, Junichi Soh, Kazunori Tsukuda, Shinichiro Miyoshi, Shinichi Toyooka. A020 Suppression of SAMSN1 Expression is Associated with the Malignant Phenotype of Hepatocellular Carcinoma. Satoshi Sueoka, Kanda Mitsuro. A021 TFF1 (Trefoil Factor Family 1) act as tumor suppressor to prevent invasive transformation of pancreatic cancer. Junpei Yamaguchi, Yukihiro Yokoyama, Toshio Kokuryo, Masato Nagino. A022 UHRF2 induced by TGF-β is a new negative regulator of EMT. Tomohiro Iguchi, Msami Ueda, Shinya Kidogami, Hisateru Komatsu, Sho Nambara, Yushi Ogawa, Kuniaki Sato, Qingjiang Hu, Tomoko Saito, Hidenari Hirata, Shotaro Sakimura, Ryutaro Uchi, Naoki Hayashi, Shuhei Ito, Hidetoshi Eguchi, Takaaki Masuda, Koshi Mimori. A023 Defining context-specific genetic vulnerabilities in human cancer cells. Eun Jee Koh, Traver Hart, Jason Moffat. A024 Detection of new pathways for tumor progression to CRPC using computational gene network based on differential gene expression profile. Aiko Sugiyama. A025 When Detecting Somatic Variants in Cancer Genomes, Is it Necessary to Sequence Matched Normal Tissue?. Michael James Clark, Elena Helman, Sean Michael Boyle, Ravi Alla, Selene Virk, Deanna Church, Shujun Luo, Gabor Bartha, Jason Harris, Nan Leng, Christian Haudenschild, Martina Lefterova, Massimo Morra, Sarah Garcia, Richard Chen, John West. A026 p53 regulates cancer cell migration and invasion through FOXF1. Takashi Tokino, Miyuki Tamura, Masashi Idogawa, Yasushi Sasaki. A027 A 3D imaging platform to stratify and monitor patients based on their level of genomic instability. Sabine Mai, Cheryl Taylor-Kashton, Celina Li, Doris Chang, Chirawadee Sathitruangsak, Julius A Awe, Jeff Saranchuk, Darrel Drachenberg, Rami Kotb, Hans Knecht. A028 Genetic difference between multicentric carcinogenesis and intrahepatic metastasis of hepatocellular carcinoma. Yutaka Midorikawa, Shogo Yamamoto, Kenji Tatsuno, Hiroki Ueda, Shingo Tsuiji, Genta Nagae, Tadatoshi Takayama, Hiroyuki Aburatani. DNA damage and repair A029 Proteomics of site-specific ADP-ribosylation profiling of DNA-dependent PARPs and histones.. Jean-Philippe Gagne, Marie-France Langelier, Amanda A Riccio, John M Pascal, Daniel Figeys, Guy G Poirier. A030 Estrogen induces RAD51C expression and localization to sites of DNA damage.. Marina K Holz. A031 Oxypeucedanin-mediated Growth Inhibition by G2/M Phase Cell Cycle Arrest in Human Hepatoma SK-Hep-1 cells. So Hyun Park, Ji-Young Hong, Jinwoong Kim, Sang Kook Lee. A032 Roles of RUNX proteins in DNA damage repair. Vaidehi Krishnan, Lavina Tay, Yoshiaki Ito. A033 In vivo and in vitro studies investigating the use of acetaminophen as a cisplatin chemo- sensitizing agent. Alexander Neuwelt, Tam Nguyen, Jeffrey Wu, Leslie Muldoon, Edward A Neuwelt. A034 Epigenetic dysregulation of satellite RNAs expression in senescent cells. Akiko Takahashi, Yoshinori Imai, Eiji Hara. A035 Hypoxia suppresses DNA repair in colon cancer stem cells which sensitizes them to hypoxia-activated pro-drugs. Jennifer Jongen, Kari Trumpi, Lizet van der Waals, Onno Kranenburg, Inne Borel Rinkes. A036 Sensing and signaling of DNA damage by master checkpoint kinase ATM and ATR. Bunsyo Shiotani, Hitoshi Zembutsu. A037 BRCA status prediction in breast cancer by gamma-tubulin immunofluorescence. Gou Watanabe, Chiba Natsuko, Tadashi Nomizu, Akihiko Furuta, Minoru Miyashita, Hiroshi Tada, Akihiko Suzuki, Takanori Ishida, Noriaki Ohuchi. A038 Search for Lynch-syndrome patients by screening of sporadic cases of endometrial cancer; expression analysis of mismatch-repair genes both in early and advanced lesions. Harumi Saeki, Kazunori Kajino, Okio Hino. A039 Functional effects of mutL-alpha genes on prostate cancer cell. Shinichiro Fukuhara, Yozo Mitsui, Ryan K Wong, Mitsuho Imai-Sumida, Soichiro Yamamura, Shahana Majid, Sharanjot Saini, Varahram Shahryari, Guoren Deng, Rajvir Dahiya, Hiroaki Shiina, Norio Nonomura, Yuichiro Tanaka. Epigenetics A040 Hookah Smoke Induces Epigenomic Alterations and Gene Expression Profiles Similar to those Mediated by Cigarette Smoke in Normal and Immortalized Human Respiratory Epithelia and Lung Cancer Cells. Yin Xiong, Sichuan Xi, Jigui Shan, Elvin Hekimoglu, Mary Zhang, Said Azoury, Julie A Hong, David S. Schrump. A041 Novel phosphorylation of CENP-A contributes to chromosomal instability and cancer progression. Mamoru Takada, Weiguo Zhang, Aussie Suzuki, Taruho Kuroda, Zhouliang Yu, Hiroyuki Inuzuka, Christopher Fry, Guohong Li, David Pellman, GARY KARPEN, Wenyi Wei, Qing Zhang. A042 Invention of DNA methylation markers for diagnosis of pancreatic cancer. Keiko Shinjo, Keisuke Katsushima, Genta Nagae, Hiroyuki Aburatani, Kenji Yamao, Yutaka Kondo. A043 Critical roles of the c-Myb/c-Kit pathway in maintenance of leukemia stem cells. Yukiko Aikawa, Issay Kitabayashi. A044 Epigenome landscape of human normal purified hepatocytes and genome-epigenome interaction: analysis by the International Human Epigenome Consortium (IHEC). Eri Arai, Fumihito Miura, Yasushi Totoki, Satoshi Yamashita, Ying Tian, Masahiro Gotoh, Hidenori Ojima, Hiroyuki Nakagawa, Yoriko Takahashi, Hiromi Nakamura, Natsuko Hama, Mamoru Kato, Hiroshi Kimura, Yutaka Suzuki, Takashi Ito, Tatsuhiro Shibata, Yae Kanai. A045 DNA methylation
Load more

Recommended publications
  • Guidelines for the Management of Hereditary Colorectal Cancer
    Guidelines Guidelines for the management of hereditary Gut: first published as 10.1136/gutjnl-2019-319915 on 28 November 2019. Downloaded from colorectal cancer from the British Society of Gastroenterology (BSG)/Association of Coloproctology of Great Britain and Ireland (ACPGBI)/ United Kingdom Cancer Genetics Group (UKCGG) Kevin J Monahan ,1,2 Nicola Bradshaw,3 Sunil Dolwani,4 Bianca Desouza,5 Malcolm G Dunlop,6 James E East,7,8 Mohammad Ilyas,9 Asha Kaur,10 Fiona Lalloo,11 Andrew Latchford,12 Matthew D Rutter ,13,14 Ian Tomlinson ,15,16 Huw J W Thomas,1,2 James Hill,11 Hereditary CRC guidelines eDelphi consensus group ► Additional material is ABSTRact having a family history of a first-degree relative published online only. To view Heritable factors account for approximately 35% of (FDR) or second degree relative (SDR) with CRC.2 please visit the journal online (http:// dx. doi. org/ 10. 1136/ colorectal cancer (CRC) risk, and almost 30% of the While highly penetrant syndromes such as Lynch gutjnl- 2019- 319915). population in the UK have a family history of CRC. syndrome (LS), familial adenomatous polyposis (FAP) The quantification of an individual’s lifetime risk of and other polyposis syndromes account for account For numbered affiliations see end of article. gastrointestinal cancer may incorporate clinical and for only 5–10% of all CRC diagnoses, advances molecular data, and depends on accurate phenotypic in genetic diagnosis, improvements in endoscopic Correspondence to assessment and genetic diagnosis. In turn this may surgical control, and medical and lifestyle interven- Dr Kevin J Monahan, Family facilitate targeted risk-reducing interventions, including tions provide opportunities for CRC prevention and Cancer Clinic, St Mark’s endoscopic surveillance, preventative surgery and effective treatment in susceptible individuals.
    [Show full text]
  • The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Inherited Polyposis Syndromes Daniel Herzig, M.D
    CLINICAL PRACTICE GUIDELINES The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Inherited Polyposis Syndromes Daniel Herzig, M.D. • Karin Hardimann, M.D. • Martin Weiser, M.D. • Nancy Yu, M.D. Ian Paquette, M.D. • Daniel L. Feingold, M.D. • Scott R. Steele, M.D. Prepared by the Clinical Practice Guidelines Committee of The American Society of Colon and Rectal Surgeons he American Society of Colon and Rectal Surgeons METHODOLOGY (ASCRS) is dedicated to ensuring high-quality pa- tient care by advancing the science, prevention, and These guidelines are built on the last set of the ASCRS T Practice Parameters for the Identification and Testing of management of disorders and diseases of the colon, rectum, Patients at Risk for Dominantly Inherited Colorectal Can- and anus. The Clinical Practice Guidelines Committee is 1 composed of society members who are chosen because they cer published in 2003. An organized search of MEDLINE have demonstrated expertise in the specialty of colon and (1946 to December week 1, 2016) was performed from rectal surgery. This committee was created to lead interna- 1946 through week 4 of September 2016 (Fig. 1). Subject tional efforts in defining quality care for conditions related headings for “adenomatous polyposis coli” (4203 results) to the colon, rectum, and anus, in addition to the devel- and “intestinal polyposis” (445 results) were included, us- opment of Clinical Practice Guidelines based on the best ing focused search. The results were combined (4629 re- available evidence. These guidelines are inclusive and not sults) and limited to English language (3981 results), then prescriptive.
    [Show full text]
  • Familial Adenomatous Polyposis Polymnia Galiatsatos, M.D., F.R.C.P.(C),1 and William D
    American Journal of Gastroenterology ISSN 0002-9270 C 2006 by Am. Coll. of Gastroenterology doi: 10.1111/j.1572-0241.2006.00375.x Published by Blackwell Publishing CME Familial Adenomatous Polyposis Polymnia Galiatsatos, M.D., F.R.C.P.(C),1 and William D. Foulkes, M.B., Ph.D.2 1Division of Gastroenterology, Department of Medicine, The Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montreal, Quebec, Canada, and 2Program in Cancer Genetics, Departments of Oncology and Human Genetics, McGill University, Montreal, Quebec, Canada Familial adenomatous polyposis (FAP) is an autosomal-dominant colorectal cancer syndrome, caused by a germline mutation in the adenomatous polyposis coli (APC) gene, on chromosome 5q21. It is characterized by hundreds of adenomatous colorectal polyps, with an almost inevitable progression to colorectal cancer at an average age of 35 to 40 yr. Associated features include upper gastrointestinal tract polyps, congenital hypertrophy of the retinal pigment epithelium, desmoid tumors, and other extracolonic malignancies. Gardner syndrome is more of a historical subdivision of FAP, characterized by osteomas, dental anomalies, epidermal cysts, and soft tissue tumors. Other specified variants include Turcot syndrome (associated with central nervous system malignancies) and hereditary desmoid disease. Several genotype–phenotype correlations have been observed. Attenuated FAP is a phenotypically distinct entity, presenting with fewer than 100 adenomas. Multiple colorectal adenomas can also be caused by mutations in the human MutY homologue (MYH) gene, in an autosomal recessive condition referred to as MYH associated polyposis (MAP). Endoscopic screening of FAP probands and relatives is advocated as early as the ages of 10–12 yr, with the objective of reducing the occurrence of colorectal cancer.
    [Show full text]
  • Effect Modification of Vitamin D Supplementation By
    nutrients Article Effect Modification of Vitamin D Supplementation by Histopathological Characteristics on Survival of Patients with Digestive Tract Cancer: Post Hoc Analysis of the AMATERASU Randomized Clinical Trial Hideyuki Yonaga 1,2, Shinya Okada 3 , Taisuke Akutsu 1, Hironori Ohdaira 4, Yutaka Suzuki 4 and Mitsuyoshi Urashima 1,* 1 Division of Molecular Epidemiology, The Jikei University School of Medicine, 3–25–8, Nishi-Shimbashi, Minato-Ku, Tokyo 105-8461, Japan; [email protected] (H.Y.); [email protected] (T.A.) 2 Celgene K. K., JP TOWER 2–7–2 Marunouchi Chiyoda-ku, Tokyo 100-7010, Japan; [email protected] 3 Department of Pathology, International University of Health and Welfare Hospital, 537–3 Iguchi, Nasushiobara, Tochigi 329-2763, Japan; [email protected] 4 Department of Surgery, International University of Health and Welfare Hospital, 537–3 Iguchi, Nasushiobara, Tochigi 329-2763, Japan; [email protected] (H.O.); [email protected] (Y.S.) * Correspondence: [email protected]; Tel.: +81-3-3433-1111 (ext. 2405) Received: 13 September 2019; Accepted: 21 October 2019; Published: 22 October 2019 Abstract: Some coauthors of this study previously performed the AMATERASU randomized, double-blind, placebo-controlled trial of postoperative oral vitamin D supplementation (2000 IU/day) in 417 patients with stage I to III digestive tract cancer from the esophagus to the rectum who underwent curative surgery (UMIN000001977). We conducted a post-hoc analysis of the AMATERASU trial to explore the effects of modification of vitamin D supplementation by histopathological characteristics on survival. Among patients with poorly differentiated adenocarcinoma, the 5-year relapse-free survival rate of patients supplemented with vitamin D was 91% compared with 63% in the placebo group (hazard ratio [HR], 0.25; 95% confidence interval [CI], 0.08 to 0.78; P = 0.017; P for interaction = 0.023).
    [Show full text]
  • Risk Factors Associated with Rectal Neuroendocrine Tumors: a Cross-Sectional Study
    Author Manuscript Published OnlineFirst on May 9, 2014; DOI: 10.1158/1055-9965.EPI-14-0132 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Risk Factors Associated with Rectal Neuroendocrine Tumors: A Cross-Sectional Study Yoon Suk Jung1, Kyung Eun Yun2, Yoosoo Chang2,3, Seungho Ryu2,3, Jung Ho Park1, Hong Joo Kim1, Yong Kyun Cho1, Chong Il Sohn1, Woo Kyu Jeon1, Byung Ik Kim1, and Dong Il Park1 1Department of Internal Medicine, 2Center for Cohort Studies, Total Healthcare Center, 3Department of Occupational and Environmental Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University, School of Medicine, Seoul, Korea Running title: Risk factors for rectal neuroendocrine tumors Corresponding author: Dong Il Park, MD, PhD Department of Internal Medicine Kangbuk Samsung Hospital Sungkyunkwan University School of Medicine 108, Pyung-Dong, Jongro-Ku, Seoul, Korea 110-746 Phone: +82-2-2001-2059, Fax: +82-2-2001-2049 E-mail: [email protected] Disclosure of Potential Conflicts of Interest: We have nothing to disclose. 1 Downloaded from cebp.aacrjournals.org on October 1, 2021. © 2014 American Association for Cancer Research. Author Manuscript Published OnlineFirst on May 9, 2014; DOI: 10.1158/1055-9965.EPI-14-0132 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Abstract Background: The incidence of rectal neuroendocrine tumors (NETs) has been increasing since the implementation of the screening colonoscopy. However, very little is known about risk factors associated with rectal NETs. We examined the prevalence of and the risk factors for rectal NETs in a Korean population.
    [Show full text]
  • (ACRCSP) Post Polypectomy Surveillance Guidelines
    Alberta Colorectal Cancer Screening Program (ACRCSP) Post Polypectomy Surveillance Guidelines June 2013 ACRCSP Post Polypectomy Surveillance Guidelines - 2 TABLE OF CONTENTS Background ………………………………………………………………………………………... 3 Terms, Definitions and Practical Points……………………………………………………….. 4 Post Colonoscopy Screening……………………………………………………………………. 5 Post Polypectomy Surveillance…………………………………………………………………..6 References ………………………………………………………………………………………….12 ACRCSP Post Polypectomy Surveillance Guidelines - 3 Background Adherence to evidence based guidelines is supported by the reduction of interval colorectal cancers and colorectal cancer (CRC)- related mortality. Surveillance interval guidelines are based on the presumption that a high quality baseline colonoscopy was performed (i.e. that the colonoscopy was completed to the cecum, and that the colonic mucosa was well visualized). It is also important to ensure the completeness of polypectomy and that all polypectomy material was sent to pathology. Patients with a failed colonoscopy (for example due to inability to reach cecum or poor bowel preparation) should undergo repeat colonoscopy (either by same operator or referred, depending on the reason why the colonoscopy was incomplete) or, less preferably, diagnostic imaging of the colon by CT colonography. A system should be in place to ensure that all pathology reports are reviewed and that recommendations to primary care physician regarding surveillance intervals are adjusted as indicated. Endoscopists should make clear recommendations to primary care physicians about the need for and timing of subsequent colonoscopy. Considering that the recommendation largely depends on the histological findings, interval recommendation in patients with polyps should account for the pathology report instead of being made at the time of colonoscopy. The decision regarding surveillance interval should be based on the most advanced finding(s) at baseline colonoscopy.
    [Show full text]
  • Location of Colorectal Adenomas and Serrated Polyps in Patients Under Age 50
    International Journal of Colorectal Disease (2019) 34:2201–2204 https://doi.org/10.1007/s00384-019-03445-5 SHORT COMMUNICATION Location of colorectal adenomas and serrated polyps in patients under age 50 Zexian Chen1,2 & Jiancong Hu1,2 & Zheyu Zheng1,2 & Chao Wang3 & Dezheng Lin1 & Yan Huang3 & Ping Lan1,2 & Xiaosheng He1,2 Accepted: 25 October 2019 /Published online: 18 November 2019 # Springer-Verlag GmbH Germany, part of Springer Nature 2019 Abstract Background The incidence of colorectal cancer, especially located in distal colorectum, is rising markedly in young patients. Conventional adenomas and serrated polyps have been widely recognized as precursors of colorectal cancer. Aim To investigate the correlation of polyp feature with polyp location in patients under age 50. Method Patients under age 50 who had received colonoscopy were included from 2010 to 2018. Clinical data including number, location, size, and histopathology of polyps were collected. Odd ratios and 95% confidence interval of adenomas with their location were calculated. Result In total, 25,636 patients aged 18–49 were enrolled, among which 4485 patients had polyps, with polyp detection rate of 17.5%. A total of 2484 and 2387 patients had conventional adenomas and serrated polyps, respectively. 76.0% advanced adenomas and 69.5% ≥ 10-mm serrated polyps were located in the distal colorectum. The detection rate of advanced adenomas was higher in patients aged 45–49. Patients with adenomas especially advanced adenomas in the distal colorectum were more likely to have advanced adenoma in the proximal colon. Conclusion Among patients under age 50, advanced adenomas and ≥ 10-mm serrated polyps were predominantly in the distal colorectum.
    [Show full text]
  • Increased EZH2 Expression During the Adenoma‑Carcinoma Sequence in Colorectal Cancer
    ONCOLOGY LETTERS 16: 5275-5281, 2018 Increased EZH2 expression during the adenoma‑carcinoma sequence in colorectal cancer MAYUKO OHUCHI1, YASUO SAKAMOTO1, RYUMA TOKUNAGA1, YUKI KIYOZUMI1, KENICHI NAKAMURA1, DAISUKE IZUMI1, KEISUKE KOSUMI1, KAZUTO HARADA1, JUNJI KURASHIGE1, MASAAKI IWATSUKI1, YOSHIFUMI BABA1, YUJI MIYAMOTO1, NAOYA YOSHIDA1, TAKASHI SHONO2, HIDEAKI NAOE2, YUTAKA SASAKI2 and HIDEO BABA1 Departments of 1Gastroenterological Surgery, and 2Gastroenterology and Hepatology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto 860-8556, Japan Received December 13, 2016; Accepted May 11, 2017 DOI: 10.3892/ol.2018.9240 Abstract. The adenoma-carcinoma sequence, the sequential from formalin‑fixed paraffin‑embedded blocks and reverse mutation and deletion of various genes by which colorectal transcription-quantitative polymerase chain reaction analysis cancer progresses, is a well-established and accepted concept of these genes was performed. Ki-67 and EZH2 expression of colorectal cancer carcinogenesis. Proteins of the polycomb scores increased significantly during the progression of repressive complex 2 (PRC2) function as transcriptional normal mucosa to adenoma and carcinoma (P=0.009), and repressors by trimethylating histone H3 at lysine 27; the EZH2 expression score was positively associated with Ki-67 activity of this complex is essential for cell proliferation expression score (P=0.02). Conversely, p21 mRNA and and differentiation. The histone methyltransferase enhancer protein expression decreased significantly, whereas expression of zeste homolog 2 (EZH2), an essential component of of p27 and p16 did not change significantly. During the PRC2, is associated with the transcriptional repression of carcinogenesis sequence from normal mucosa to adenoma and tumor suppressor genes. EZH2 expression has previously carcinoma, EZH2 expression increased and p21 expression been reported to increase with the progression of pancreatic decreased significantly.
    [Show full text]
  • Copyrighted Material
    Subject index Note: page numbers in italics refer to fi gures, those in bold refer to tables Abbreviations used in subentries abdominal mass patterns 781–782 GERD – gastroesophageal refl ux disease choledochal cysts 1850 perception 781 IBD – infl ammatory bowel disease mesenteric panniculitis 2208 periodicity 708–709 mesenteric tumors 2210 peripheral neurogenic 2429 A omental tumors 2210 pharmacological management 714–717 ABCB1/MDR1 484 , 633 , 634–636 abdominal migrane (AM) 712 , 2428–2429 physical examination 709–710 , 710 ABCB4 abdominal obesity 2230 postprandial 2498–2499 c h o l e s t e r o l g a l l s t o n e s 1817–1818 , abdominal pain 695–722 in pregnancy 842 1819–1820 a c u t e see acute abdominal pain prevalence 695 functions 483–484 , 1813 acute cholecystitis 784 rare/obscure causes 712–713 , 712 intrahepatic cholestasis of pregnancy 848 acute diverticulitis 794–796 , 795 , 1523–1524 , red fl ags 713 low phospholipid-associated 1527 relieving/aggravating factors 709 cholelithiasis 1810 , 1819–1820 , 2393 acute mesenteric ischemia 2492 right lower quadrant 794 m u t a t i o n p h e n o t y p e s 2392 , 2393 a c u t e p a n c r e a t i t i s 795 , 1653 , 1667 right upper quadrant 794 progressive familial intrahepatic cholestasis-3 acute suppurative peritonitis 2196 sickle cell crisis 2419 494 adhesions 713 s i t e 703 , 708 ABCB11 see bile salt export pump (BSEP) AIDS 2200 special pain syndromes 718–720 ABCC2/MRP2 485 , 494 , 870 , 1813 , 2394 , 2395 anxiety 706–707 sphincter of Oddi dysfunction 1877 ABCG2/BCRP 484–485 , 633
    [Show full text]
  • Common Surgical Diseases.Pdf
    Common Surgical Diseases Second Edition Common Surgical Diseases An Algorithmic Approach to Problem Solving Second Edition Edited by Jonathan A. Myers, MD Assistant Professor of Surgery Director, Undergraduate Surgical Education Rush Medical College of Rush University Rush University Medical Center Chicago, IL 60612, USA Keith W. Millikan, MD Professor of Surgery Associate Dean, Surgical Sciences and Services Rush Medical College of Rush University Rush University Medical Center Chicago, IL 60612, USA Theodore J. Saclarides, MD Professor of Surgery Head, Section of Colon and Rectal Surgery Rush Medical College of Rush University Rush University Medical Center Chicago, IL 60612, USA Jonathan A. Myers, MD Keith W. Millikan, MD Assistant Professor of Surgery Professor of Surgery Director, Undergraduate Surgical Education Associate Dean, Surgical Sciences and Services Rush Medical College of Rush University Rush Medical College of Rush University Rush University Medical Center Rush University Medical Center Chicago, IL 60612, USA Chicago, IL 60612, USA Theodore J. Saclarides, MD Professor of Surgery Head, Section of Colon and Rectal Surgery Rush Medical College of Rush University Rush University Medical Center Chicago, IL 60612, USA ISBN 978-0-387-75245-7 e-ISBN 978-0-387-75246-4 Library of Congress Control Number: 2007937163 © 2008 Springer Science+Business Media, LLC All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden.
    [Show full text]
  • References Chapter 1 Immunostains: Introduction 1
    References Chapter 1 Immunostains: Introduction 1. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982;31:11–24. 2. Moll R, Divo M, Langbein L. The human keratins: biology and pathology. Histochem. Cell Biol. 2008;129:705–733. 3. Chu PG, Weiss LM. Keratin expression in human tissues and neoplasms. Histopathology 2002;40:403–439. 4. Cooper D, Schermer A, Sun TT. Classification of human epithelia and their neoplasms using monoclonal antibodies to keratins: strategies, applications, and limitations. Lab. Invest. 1985;52:243–256. 5. Dabbs DJ. Diagnostic Immunohistochemistry: Theranostic and Genomic Applications. 3rd ed. New York: Saunders; 2010. 6. Taylor CR, Cote RJ. Immunomicroscopy: A Diagnostic Tool for the Surgical Pathologist. 3rd ed. Philadelphia: Saunders; 2006. 7. True L. Atlas of Diagnostic Immunohistopathology. Philadelphia: Lippincott Williams & Wilkins; 1990. 8. Zhang PJ, Shah M, Spiegel GW, Brooks JJ. Cytokeratin 7 immunoreactivity in rectal adenocarcinomas. Appl. Immunohistochem. Mol. Mor- phol. 2003;11:306–310. 9. Carpentieri DF, Nichols K, Chou PM, Matthews M, Pawel B, Huff D. The expression of WT1 in the differentiation of rhabdomyosarcoma from other pediatric small round blue cell tumors. Mod. Pathol. 2002;15:1080–1086. 10. Montgomery E, Lee JH, Abraham SC, Wu TT. Superficial fibromatoses are genetically distinct from deep fibromatoses. Mod. Pathol. 2001;14:695–701. 11. Aleixo PB, Hartmann AA, Menezes IC, Meurer RT, Oliveira AM. Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferen- tiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours.
    [Show full text]
  • Association Between Colorectal Adenoma and Carotid Atherosclerosis in Korean Adults
    International Journal of Environmental Research and Public Health Article Association between Colorectal Adenoma and Carotid Atherosclerosis in Korean Adults Hyunji Kim 1, Yoon Jeong Cho 1,* , Yun A. Kim 1 and Sang Gyu Gwak 2 1 Department of Family Medicine, School of Medicine, Daegu Catholic University, Daegu 42472, Korea; [email protected] (H.K.); [email protected] (Y.A.K.) 2 Department of Medical Statistics, School of Medicine, Daegu Catholic University, Daegu 42472, Korea; [email protected] * Correspondence: [email protected]; Tel.: +82-53-650-4114; Fax: 82-53-650-4122 Received: 29 October 2018; Accepted: 4 December 2018; Published: 6 December 2018 Abstract: Background: Colorectal neoplasm, including colorectal adenoma, is associated with old age, cigarette smoking, and the presence of metabolic syndromes. These are also risk factors for cardiovascular disease. Carotid ultrasonography is a noninvasive test that can predict the risk of cardiovascular disease and may be another test that may provide indications of these risk factors. This study aimed to investigate the association between colorectal adenomatous polyps and carotid atherosclerosis. Methods: This study included 548 adults who underwent colonoscopy and carotid ultrasonography for a health examination between March 2013 and December 2017 at a university hospital in South Korea. Abnormal carotid sonography findings included either increased carotid intima-media thickness or presence of carotid plaques. Results: The proportion of subjects with overall colorectal adenomatous polyps was 31.0% (170/548). Colorectal adenoma was more prevalent in the presence of abnormal carotid ultrasonography findings (38.6% vs. 27.6%, p = 0.013). Colorectal adenomatous polyp was significantly associated with abnormal carotid ultrasonography findings (OR = 1.65; 95% CI, 1.12–2.42, p = 0.011) in a multivariate analysis after adjusting for age, sex, cigarette smoking, alcohol consumption, and presence of metabolic syndrome.
    [Show full text]